hotspot -WSS

hotspot

author：leisure time 2025-08-26 23:47:43 - browse：77621

Powdered ibogaine against a white background. — Tabernanthe iboga, the shrub that contains the psychedelic substance ibogaine. Wikimedia Commons

The psychedelic ibogaine is unlikely to ever receive approval as a treatment for opioid addiction, the federal government’s top addiction researcher said Thursday.

The remarks from Nora Volkow, the longtime director of the National Institute on Drug Abuse, serve as a cautionary note amid widespread enthusiasm about ibogaine, a naturally occurring substance that drug companies and researchers have increasingly cast as a potential paradigm-shifting addiction treatment.

But its potential cardiac side effects could stand in the way of receiving approval from the Food and Drug Administration, Volkow said.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Activists slam private health insurers over coverage restrictions
Next article： Pharma needs to include young adults in clinical research

focus

WSS

Cancer thrives by mutating. But sometimes, a mutation leaves it vulnerable

'Cuddling' is just what the doctor ordered for a 200

Eat, drink, but be wary — 4 foods that interact with medications

Stephen Quake on the Chan Zuckerberg quest to conquer disease

My daughter's legacy lives on through her writing, phage therapy

Curing rare childhood diseases will falter unless Congress steps up

hotspot

hotspot

focus

After affirmative action ruling, medical educators look to 'holistic review'

Curing rare childhood diseases will falter unless Congress steps up

Malaria cases in Florida and Texas: Here’s what you need to know

Flash flooding emergencies prompt evacuations in Kentucky, Tennessee

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Medical mystery: When an infection after surgery isn’t what it seems

State Dept. review finds Biden bears some blame for Afghanistan failures

Judge in Trump's Jan. 6 case gives attorneys 2 weeks to propose trial date

BioMarin wins approval for gene therapy to treat hemophilia A

Medical mystery: When an infection after surgery isn’t what it seems

leisure time

Rock icon Freddie Mercury pre

The system is set up to fail children with medical complexity

Pharma needs to include young adults in clinical research

Report captures long Covid’s disabling effects and policy challenges

How the BIOSECURE Act is already affecting U.S., Chinese life science firms

US Marines prepare to be put on commercial ships to deter Iranian harassment in Strait of Hormuz

Wikipedia

focus

hotspot

explore